Dr. Manash K Paul
Associate Professor
Department of Radiation Biology and Toxicology
CURRENT ACADEMIC ROLE & RESPONSIBILITIES
- Manash K. Paul is an Associate Professor in the Department of Radiation Biology and Toxicology at the 必威体育betway888 School of Life Sciences.?
- 必威体育betway888 Area: Stem cell, Regenerative medicine, and Cancer
- Guides doctoral, post-graduate, and graduate students for various research projects
ACADEMIC QUALIFICATIONS
| Degree | Specialisation | Institute | Year of passing |
|---|---|---|---|
| PhD | Biotechnology | National Institute of Pharmaceutical Education and 必威体育betway888, Mohali (NIPER-M) | 2008 |
| MSc | Biotechnology | Visva Bharati University, An Institute of National Importance Shantiniketan, West Bengal | 2001 |
Experience
| Institution / Organisation | Designation | Role | Tenure |
|---|---|---|---|
| 必威体育betway888 School of Life Sciences, 必威体育betway888 Academy of Higher Education | Associate Professor | 19.10.2023 Till date | |
| Kasturba Medical College, 必威体育betway888 Academy of Higher Education | Adjunct Faculty | 12.11.2022 to 18.10.2023 | |
| Department of Pulmonary and Critical Care Medicine, University of California, Los Angeles (UCLA), USA. | Assistant Project Scientist Step IV (Group ID: FACULTY) | 01.07.2020 to 22.09.2023 | |
| Department of Pulmonary and Critical Care Medicine, UCLA, USA. | Assistant Project Scientist Step I and II | 01.07.2016 to 30.06.2020 | |
| Brigitte Gompert’s Laboratory, University of California, Los Angeles (UCLA), USA. | Post Doctoral Fellow | 01.05.2012 to 05.04.2016 | |
| Volker Hartenstein’s Laboratory, University of California, Los Angeles (UCLA), USA. | Post Doctoral Fellow | 10.03.2010 to 31.04.2012 | |
| Indian Institute of Science Education and 必威体育betway888 (IISERM), Institute of National Importance, Mohali, India | Lecturer | 05.09.2007 to 01.03.20 |
AREAS OF INTEREST, EXPERTISE AND RESEARCH
Area of Expertise
Stem cell, Regenerative medicine, and Cancer
Area of 必威体育betway888
Stem cell biology in mouse and human, iPSC, ASCs, ADSCs, MSCs, directed differentiation. Organoid technology (lung, gut, brain, and pancreas), spheroids, tumoroids, tissue engineering, disease modeling, drug screening, Microfluidic Organoids-on-a-Chip technology, drug discovery, assay development. CRISPR-Cas9. o Mouse models for studying lung disease, mouse genetics, Cre-LoxP system, transgenic models, syngeneic mouse models, patient-derived xenograft models, adenocarcinoma and squamous lung cancer models, fibrosis, COPD, injury and metastatic models.